ContraVir Pharmaceuticals to Present at The MicroCap Conference 2017
October 03 2017 - 6:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, announced today it will be featured
as a presenting company at The MicroCap Conference, held in New
York City on October 5, 2017.
James Sapirstein, Chief Executive Officer, of ContraVir will
provide an overview of the Company's business and will be available
to participate in one-on-one meetings with investors who are
registered to attend the conference.
Event: The MicroCap Conference
Date: October 5, 2017
Time: 11:00 – 11:30AM (Eastern Time)
Location: The Essex House
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the
development and commercialization of targeted antiviral therapies
with a specific focus on developing a potentially curative therapy
for hepatitis B virus (HBV). The Company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™
currently in Phase 2, is designed to deliver high intrahepatic
concentrations of TFV, while minimizing off-target side-effects
caused by high levels of circulating TFV. CRV431, the other
anti-HBV compound, is a next-generation cyclophilin inhibitor with
a unique structure that increases its potency and selective index
against HBV. ContraVir is also developing Valnivudine™, an orally
available nucleoside analogue prodrug; Valnivudine™ is currently in
Phase 3 for the treatment of herpes zoster. In addition to
direct antiviral activity, Phase 2 data suggest that Valnivudine™
has the potential to reduce the incidence of debilitating
shingles-associated pain known as post-herpetic neuralgia
(PHN). For more information visit www.contravir.com.
For further information, please contact:
Sharen Pyatetskaya Director of Investor Relations
sp@contravir.com; (732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Sep 2023 to Sep 2024